Consolidated Statements of Operations and Comprehensive Loss - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Costs and Expenses:
Research and development	$ 7,163,530	$ 7,593,715	$ 13,651,987
General and administrative	3,358,091	7,000,444	7,371,885
Total Operating Expenses	10,521,621	14,594,159	21,023,872
Loss from Operations	(10,521,621)	(14,594,159)	(21,023,872)
Other Income (Expense):
Change in fair value of debt		(108,942)
Interest on debt		(339,158)
Change in fair value of derivative instruments-warrants and contingent consideration	1,062,769	5,056,964	4,224,819
Loss before income taxes	(9,458,852)	(9,985,295)	(16,799,053)
Income tax benefit	1,947,760	536,000	1,908,003
Net loss	(7,511,092)	(9,449,295)	(14,891,050)
Series C deemed dividend (see note 6)		(8,451,851)
Net loss attributable to Common Stockholders	$ (7,511,092)	$ (17,901,146)	$ (14,891,050)
Weighted Average Common Shares Outstanding
Basic	9,678,329	12,871,530	7,286,304
Diluted	9,678,329	12,871,530	7,292,327
Net loss per Common Share (see note 12)
Basic	$ (0.78)	$ (1.39)	$ (2.04)
Diluted	$ (0.78)	$ (1.39)	$ (2.41)